HLS Therapeutics Inc.
HLTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $56,619 | $63,074 | $61,467 | $60,009 |
| % Growth | -10.2% | 2.6% | 2.4% | – |
| Cost of Goods Sold | $8,997 | $7,624 | $4,981 | $3,972 |
| Gross Profit | $47,622 | $55,450 | $56,486 | $56,037 |
| % Margin | 84.1% | 87.9% | 91.9% | 93.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $10,195 | $8,390 | $17,735 | $17,397 |
| SG&A Expenses | $26,928 | $28,286 | $35,581 | $32,057 |
| Sales & Mktg Exp. | $16,733 | $19,896 | $17,846 | $14,660 |
| Other Operating Expenses | $28,380 | $27,164 | $0 | $0 |
| Operating Expenses | $55,308 | $55,450 | $69,983 | $62,321 |
| Operating Income | -$7,686 | -$10,349 | -$13,440 | -$6,284 |
| % Margin | -13.6% | -16.4% | -21.9% | -10.5% |
| Other Income/Exp. Net | -$7,896 | -$17,454 | -$10,225 | -$5,524 |
| Pre-Tax Income | -$15,582 | -$27,803 | -$23,722 | -$11,808 |
| Tax Expense | $4,073 | -$272 | -$124 | $1,309 |
| Net Income | -$19,655 | -$27,531 | -$23,598 | -$13,117 |
| % Margin | -34.7% | -43.6% | -38.4% | -21.9% |
| EPS | -0.62 | -0.85 | -0.73 | -0.41 |
| % Growth | 27.1% | -16.4% | -78% | – |
| EPS Diluted | -0.62 | -0.85 | -0.73 | -0.41 |
| Weighted Avg Shares Out | 31,839 | 32,263 | 32,433 | 32,184 |
| Weighted Avg Shares Out Dil | 31,839 | 32,263 | 32,433 | 32,184 |
| Supplemental Information | – | – | – | – |
| Interest Income | $304 | $350 | $57 | $44 |
| Interest Expense | $10,083 | $8,748 | $7,317 | $6,956 |
| Depreciation & Amortization | $22,717 | $31,939 | $33,039 | $29,998 |
| EBITDA | $17,218 | $12,884 | $17,284 | $25,188 |
| % Margin | 30.4% | 20.4% | 28.1% | 42% |